LP
Lucid Peptides
Research Grade

Research Summary

GHRP-2

Research Hub
Clinical — 10 studies

GHRP-2 is a synthetic hexapeptide investigated for its ability to stimulate growth hormone secretion via ghrelin receptor pathways.

Being studied for

Growth hormone releaseAppetite and ghrelin signaling research

Published Research

Evidence profile

Controlled human evidence

10 cited publications · 4 primary trials

Findings below belong to the studies that reported them. They describe the material and conditions those authors used, not this product, and not an outcome to expect.

Supporting evidence

ClinicalPrimary trial

The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone

Van den Berghe G et al. · Clinical endocrinology · 2002

The study reportedCoadministration of GHRP-2, TRH and GnRH reactivated the GH, TSH and LH axes in prolonged critically ill men and evoked beneficial metabolic effects which were absent with GHRP-2 infusion alone and only partially present with GHRP-2 + TRH.

PMID 12030918DOI 10.1046/j.1365-2265.2002.01255.x
View on PubMed
ClinicalPrimary trial

Synergy of L-arginine and GHRP-2 stimulation of growth hormone in men and women: modulation by exercise

Wideman L et al. · American journal of physiology. Regulatory, integrative and comparative physiology · 2000

The study reportedExercise potentiated the individual stimulatory actions of A and G, while blunting the relative magnitude of the synergistic (supra-additive) interaction observed at rest.

PMID 11004017DOI 10.1152/ajpregu.2000.279.4.R1467
View on PubMed
ClinicalPrimary trial

Growth hormone-releasing peptide-2 infusion synchronizes growth hormone, thyrotrophin and prolactin release in prolonged critical illness

Van den Berghe G et al. · European journal of endocrinology · 1999

The study reportedThe nocturnal GH, TSH and PRL secretory patterns during prolonged critical illness are herewith further characterized to include loss of synchrony among GH, TSH and PRL release.

PMID 10037246DOI 10.1530/eje.0.1400017
View on PubMed
ClinicalPrimary trial

Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature

Pihoker C et al. · The Journal of endocrinology · 1997

The study reportedGHBP concentrations rose significantly, from 439 +/- 63 pmol/l to 688 +/- 48 pmol/l. In this study, intranasal GHRP-2 administration was well tolerated, and produced a modest but significant increase in growth velocity.

PMID 9390009DOI 10.1677/joe.0.1550079
View on PubMed
Additional indexed literature (6)

Published studies summarised here concern the specific investigational or pharmaceutical materials and study conditions described by their authors. Their findings are not performance claims for Lucid Peptides material. Citations verified against PubMed on 2026-08-09.

View full peptide profile for GHRP-2
All Research
[Notice]All information on this page is provided strictly for laboratory research and educational purposes only.